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Background: Ischemic postconditioning (PostC), reperfusion in brief cycles, is known to induce short-term
reduction in infarct size in patients with ST elevation myocardial infarction (STEMI), especially among those with
large myocardium at risk (MaR). The aim of the present study was to investigate the long-term effect of PostC on
infarct size and left ventricular ejection fraction (LVEF).
Methods: Sixty-eight patients with a first STEMI were randomised to primary percutaneous coronary intervention
(PCI) (n = 35) or PCI followed by PostC (n = 33). MaR was determined as abnormally contracting segments on left
ventricular angiogram. Cardiac magnetic resonance was performed at 3 and 12 months for the determination of
infarct size and LVEF.
Results: Overall there was no difference in infarct size expressed in percentage of MaR between patients
randomised to the control (31%; 23, 41) and PostC (31%; 23, 43) groups at 12 months. Likewise there was no
difference in LVEF between control (49%; 41, 55) and PostC (52%; 45, 55). In contrast, patients in the PostC group
with MaR in the upper quartile had a significantly smaller infarct size (29%; 18, 38) than those in the control group
(40%; 34, 48; p < 0.05) at 12 months. In these patients LVEF was higher in the PostC (47%; 43, 50) compared to the
control group (38%; 34, 42; p < 0.01).
Conclusions: In this long-term follow-up study PostC did not reduce infarct size in relation to MaR or improved
LVEF in the overall study population. However, the present data suggest that PostC exerts long-term beneficial
effects in patients with large MaR thereby extending previously published short-term observations.
Trial registration: Karolinska Clinical Trial Registration (http://www.kctr.se). Unique identifier: CT20080014
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Myocardial infarction (MI) remains a major health prob-
lem despite substantial improvements in detection and
treatment [1]. Infarct size is a major determinant of sub-
sequent mortality and morbidity [2,3]. Accordingly,
therapeutic strategies aimed at limiting infarct size are of
great prognostic importance in addition to current man-
agement strategies focused on early revascularisation
with thrombolysis or primary percutaneous coronary* Correspondence: peder.sorensson@karolinska.se
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distribution, and reproduction in any mediumintervention (PCI) stabilization [4]. Although opening of
the infarct-related artery is beneficial it also initiates a
series of harmful events including release of reactive free
oxygen species and calcium overload that triggers the
opening of the mitochondrial permeability transition
pore (mPTP) [5]. This contributes to further myocyte
necrosis and apoptosis, the so called reperfusion injury
[6]. The reperfusion injury opens for therapeutic inter-
ventions aiming at myocardial protection with limitation
of the final infarct size. Accumulating evidence suggests
that postconditioning (PostC), repetitive brief cycles of
ischemia and reperfusion during early reperfusion, reduces
infarct size in experimental and clinical studies of patients
with ST-elevation myocardial infarctions (STEMI) [7-11].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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of the mPTP through different pathways of kinases in-
volving the reperfusion injury salvage kinase and the
survivor activating factor enhancement pathway within
the myocyte [12,13].
Previous studies employing PostC have mainly had
short-term follow-up periods evaluating either plasma
biomarkers of myocardial injury (creatine kinase or tro-
ponins) [9], infarct size [7,8] or left ventricular ejection
fraction (LVEF) [14]. However, data concerning long-
term (≥ 12 months) follow-up of patients treated with
PostC are limited and no study has previously deter-
mined the effect of PostC on infarct size and LV func-
tion using cardiovascular magnetic resonance (CMR)
imaging during a period of one year in patients with
STEMI. The aim of the present study was therefore to
investigate the long-term effect of PostC on infarct size
in patients with STEMI in a randomised study. We have
previously demonstrated that PostC reduced infarct size
determined by CMR among patients with large myocar-
dium at risk (MaR) [8]. The present study is a pre-




During April 2007 and March 2009 a total of 795 patients
were referred to the coronary care unit at Karolinska Uni-
versity Hospital in Stockholm for a PCI due to STEMI of
whom 89 were randomised and 76 completed the study
protocol [8]. Patients were eligible for enrolment if they
fulfilled the following inclusion criteria: men and women
older than 18 years, chest pain >30 min and <6 h, ST ele-
vation >0.1 mV (>0.2 mV in V1-V3) in two contiguous
ECG leads or left bundle branch block, and a thrombolysis
in myocardial infarction (TIMI) grade 0 flow in the infarct
related artery. Exclusion criteria were previous myocardial
infarction, previous coronary artery bypass surgery, car-
diogenic shock, contraindication for CMR and persistent
atrial fibrillation. A biplane (30º right anterior oblique, 60º
left anterior oblique) left ventriculography was performed
before revascularisation and MaR was estimated by meas-
uring the circumferential extent of abnormally contracting
segments [15]. Following this the patients were random-
ized to primary PCI only or PCI followed by PostC, in
blocks of eight, following stratification for LAD and non-
LAD occlusions. PostC was performed by reinflating the
balloon at the same location to a pressure of 2–4 atm for
60 s starting 60 s after the initial reperfusion. This cycle
was performed four times. The PCI intervention was com-
pleted by a coronary angiogram to study the final TIMI
flow. Collateral flow to the infarct zone was assessed on
the initial angiogram before PCI and graded on a scale of
0 to 3 [16]. All patients that underwent complete CMRprotocol at three and 12 months were included in the final
analysis. The study was performed according to the
Declaration of Helsinki and good clinical practice [17].
Written informed consent was given by all patients. The
study was approved by the local ethics committee at the
Karolinska Institutet.
CMR protocol
A standard CMR examination was performed after three
and 12 months. These investigations were performed in
the supine position with an 8-channel cardiac coil by
means of a 1.5 T system (Signa Excite TwinSpeed, General
Electric Healthcare, Waukesha, Wisconsin, USA) during
vector-ECG monitoring. Gadolinium contrast (0.2 mmol/
kg; Omniscan, GE Healthcare) was administered before
positioning the patient in the scanner. The image protocol
included scout images, localisation of the short axis and
then covering the whole left ventricle (LV) with retro-
spectively gated cine steady-state free precession (SSFP)
images. The following parameters were typically used;
SSFP (echo time (TE) 1.58 ms, repetition time (TR)
3.61 ms, flip angle 60º, 25 phases, 8 mm slice, no gap,
matrix, 226 × 226). Late gadolinium enhancement (LGE)
images were acquired 15–20 min after contrast injection
using an inversion recovery gradient echo sequence (TE
3.3 ms, TR 7.0 ms, inversion time 180–250 ms to null the
myocardium, 8 mm slice, no gap, matrix 256 × 192) in the
same slice orientation as cine SSFP images. Each slice was
obtained during end-expiratory breath holding. Two-,
three- and four-chamber views were also obtained to con-
firm the findings.
Data analysis
All CMR images were analysed blinded and off-line
using a freely available segmentation software (Segment
V.1.8 R1405; http://segment.heiberg.se/) [18]. End-diastolic
and end-systolic volumes were measured in the phase with
the largest and smallest LV volumes respectively. LVEF,
stroke volume and LV mass were calculated on cine SSFP
sequences using manual delineation of the endocardial and
epicardial borders. The papillary muscles were excluded
from the myocardium. For correct LV volumes and mass
estimations the basal slices were examined in different cine
projections. LV mass was calculated by multiplying the
myocardial volume by the density of myocardial tissue
(1.05 g/ml). All volumes were indexed to body surface area.
Infarct size was quantified on LGE images using an auto-
mated quantification method validated ex- and in vivo and
in which partial volume effects were accounted for [19].
Manual adjustments were made when the computer
algorithm was obviously wrong. Infarct size was than re-
lated to MaR for each patient. LGE images were also used
for quantifying microvascular obstruction defined as
hypoenhanced region within the infarct area. Results
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6–9 have already been published earlier while this report
presents data from three and 12 months [8], LV remodel-
ing was defined as an increase in end-systolic LV volume
≥15% from the value obtained one week after admission.
Change in LV sphericity index was used for detection of
cavity remodeling [20]. The major axis was manually mea-
sured in an end-diastolic four-chamber view starting at the
mitral annulus and ending at the apical endocardial border.
The radius was used for calculating the sphere volume.
End-diastolic LV volume was divided by the sphere volume
creating a sphericity index for every patient.
Statistical analysis
All quantitative data are presented as median and inter
quartile range. The Mann–Whitney U test was used to
test for differences in infarct size and cardiac volumes
and function between groups. Fisher’s exact test was
used to test for differences between dichotomized vari-
ables. Linear regression was used for comparing infarct
size in relation to MaR between groups and then the dif-
ference in slopes and intercepts between groups were
tested (Infarct size = Intercept + Treatment (0/1) +MaR +
Treatment (0/1)*MaR). Wilcoxon sign rank test withFigure 1 Flow chart.Bonferroni correction for multiple testing was used for
longitudinal follow-up on CMR measurements. Bland-
Altman plots were constructed for comparing intra- and
interobserver variation and calculated as the SD of the dif-
ference between two calculations divided by the average of
the two observers. Statistical analysis was performed using
GraphPad Prism V 5.0 (GraphPad Software, San Diego,




Sixty-eight patients (35 in the control group and 33 in
the PostC group) completed follow-up with CMR at three
and 12 months. The main reason for loss to follow-up was
unwillingness to complete the study protocol (Figure 1).
No sudden cardiac death or myocardial infarction occurred
in either group during follow-up. Five patients (4 controls)
were hospitalized due to congestive heart failure (n = 3) or
chest pain (n = 2) during the follow-up period. All patients
were asymptomatic at the time of follow-up CMR and
remained on the medication prescribed at the time of hos-
pital discharge with the exception of clopidogrel, which
was terminated after three months in case of bare metal
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groups were well balanced regarding clinical characteristics
and angiographic findings. There were no significant differ-
ences between groups. No differences between groups (8
controls, 9 PostC patients) were seen among patients with
MaR in the upper quartile (data not shown).
Infarct size and left ventricular ejection fraction
Median infarct size, expressed as a percentage of MaR,
at three and 12 months did not differ between the con-
trol and PostC groups (Figure 2). However, the slope of
the regression lines for the final infarct size in relation
to MaR differed significantly between the two groups, an
observation that was consistent over time (Figure 3). Pa-
tients within the upper quartile of MaR (>35% of the
LV) were therefore analyzed separately in line with the
analysis performed after one week [8]. After threeTable 1 Patient characteristics in the control and PostC
groups
Variables Control group PostC group p
n = 35 n = 33
At admission
Age, years (range) 62 (42–85) 63 (37–85) 0.96
Male sex 31 (89) 28 (85) 0.73
Body mass index, kg/m2 (IQR) 27 (25, 29) 27 (25, 31) 0.37
Ischemia time, minutes (IQR) 180 (141, 255) 165 (133, 202) 0.27
Current smokers 9 (26) 9 (27) 1.0
Hypertension 11(31) 5(15) 0.16
Previous angina 3 (9) 5 (15) 0.47
Diabetes mellitus* 10 (32) 9 (29) 1.0
Treatment on admission
Aspirin, 3 (9) 1 (3) 0.61
Beta-blockers 4 (11) 1 (3) 0.36
ACE/ARB 6 (17) 2 (6) 0.26
Statins 3 (9) 2 (6) 1.0
Treatment during angioplasty
Aspirin 35 (100) 31 (94) 0.23
Clopidogrel 34 (97) 31 (94) 0.61
Glycoprotein inhibitors 27 (77) 26 (79) 1.0
Opioids 26 (74) 28 (85) 0.37
Treatment at discharge
Aspirin, n (%) 35 (100) 32 (97) 0.49
Clopidogrel, n (%) 35 (100) 33 (100) 1.0
Beta-blockers, n (%) 34 (97) 33 (100) 1.0
ACE/ARB, n (%) 20 (57) 21 (61) 0.64
Statins, n (%) 34 (97) 32 (97) 1.0
Data are presented as median and quartiles for continuous variables except
age which is median and range, or number of patients and percentage for
dichotomous variables. ACE Angiotensin converting enzyme inhibitor; ARB
Angiotensin receptor blocker. * n = 31 both in Control and PostC.months PostC patients had a trend towards smaller in-
farct sizes than those in the control group a difference
that became significant after 12 months (Figure 4). In
contrast, there were no significant differences in infarct
size in patients within the lower quartiles of MaR (data
not shown). The intra- and interobserver variation be-
tween two blinded readers for infarct size measurement
(n = 18) was 0.2 ± 1.0 and 0.1 ± 1.3 and for LV mass (n =
12) -0.8 ± 7.0 and −0.4 ± 6.8 (mean difference ± SD),
respectively.
Median LVEF for the whole study population did not
differ between the control and PostC groups. The slope
of the regression lines describing LVEF in relation to
MaR had a trend towards improved LVEF after three
months and differed significantly between the two
groups after 12 months (Figure 5). In the group of pa-
tients in the upper quartile of MaR, LVEF was signifi-
cantly higher in the PostC group than in the control
group both after three and 12 months. LVEF at 12 -
months was 47% (43, 50) in the PostC group compared
to 38% (34, 42; p < 0.01) in the control group.
Remodeling data/parameters
LV mass index decreased significantly from one week to
12 months in both groups and there was no difference
within the control and PostC groups regarding indexed
volumetric CMR data at 3 and 12 months (Table 3). At
one week PostC indexed volumes were slightly smaller
compared to controls in the overall group. Infarct size,
in absolute grams, decreased significantly between one
week and 12 months in both groups. The mean decrease
in absolute infarct size was 30% and 32% in the control
and PostC group, respectively. The main decrease was
seen between one week and 3 months. This also affected
all other parameters that included infarct size in the cal-
culation. Adverse LV remodeling occurred in only nine
patients equally distributed between the two groups.
End-diastole LV sphericity index for the entire study
population did not differ between or within groups over
time.
Discussion
In this one year follow-up of patients with a first time
STEMI, PostC did not reduce infarct size in relation to
MaR or improve LVEF in the overall study population.
On the other hand, there was a sustained beneficial im-
pact in patients with large MaR as reflected by improved
LVEF and smaller infarct size which was persistent dur-
ing 12 months of follow up. The study therefore suggests
that PostC exerts long-term beneficial effects among pa-
tients with large MaR.
The first observations of the possibility to reduce in-
farct size by means of PostC were reported by Staat
et al. [9] and Laskey et al. [21]. They reported a reduced
Table 2 Angiographic data
Variables Control group PostC group p
n = 35 n = 33
Infarct related artery
LAD, n (%) 13 (37) 11 (33) 0.80
LCx, (%) 1 (3) 3 (9) 0.35
RCA, n (%) 21 (60) 19 (57) 1.0
Collateral flow grade 2 or 3, n (%) 6 (17) 4 (12) 0.74
Number of vessels
one-vessel disease 22 (63) 21 (64) 1.0
two-vessel disease 11 (31) 10 (30) 1.0
three-vessel disease 2 (6) 2 (6) 1.0
Abnormally contracting segments (%) 25 (15, 34) 29 (17, 38) 0.43
Direct stenting, n (%) 2 (6) 0 (0) 0.49
Thrombectomy, n (%) 2 (6) 0 (0) 0.49
Bare metal stent, n (%) 35 (100) 32 (97) 0.49
TIMI flow grade 3 after PCI, n (%) 30 (86) 31 (94) 0.43
Data are presented as median and quartiles for continuous variables except age which is median and range, or number of patients and percentage for
dichotomous variables. LAD Left anterior descending coronary artery; RCA Right coronary artery; LCx Left circumflex coronary artery; TIMI Thrombolysis in
myocardial infarction; PCI Percutaneous coronary intervention.
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serve and ST-resolution, respectively. In 2012 two stud-
ies were published with conflicting results [11,22]. Frexia
et al. were unable to verify any effect of PostC compared
with controls while Thuny et al. confirmed their original
findings of a favorable impact on infarct size and edema
[9,14]. These discrepancies may have several explana-
tions. The patients in the latter study were younger with
less comorbidity and were only subjected to direct
stenting but no thrombectomy. This is also emphasized
in a recent meta-analysis [23]. Similar differences may
also explain the results of the present study. Our popula-
tion was older (median age of 62 years) and the propor-
tion of patients with diabetes was higher than in the
study by Thuny et al. but the potential impact of
comorbidities has so far not been fully understood. Dir-
ect stenting and thrombectomy may be of importanceFigure 2 Box-plot of infarct size in relation to myocardium at risk (Ma
12 months in the control group and the postconditioning (PostC) groby decreasing distal embolisation. Since direct stenting
(n = 2) and thrombectomy (n = 2) was performed in only
four of the control patients it should be of minor im-
portance for the present results.
The first original report of the present study material,
using CMR for determination of infarct size in relation
to MaR one week after the acute myocardial infarction,
PostC did not influence infarct size in patients with
small risk areas while there was a significant reduction
among those with MaR in the highest quartile [8]. In this
long-term follow-up, it was found that infarct size and
LVEF did not differ in PostC patients in the overall study
group when re-examined after three and 12 months fol-
lowing the acute event. The slopes of the regression lines
for infarct size and LVEF as a function of MaR did, how-
ever, differ at these times of observation indicating a
sustained benefit for patients with large risk areas. BasedR) for the overall study population (n = 68) at (A) three and (B)
up.
Figure 3 Infarct size (expressed in relation to left ventricular
mass) plotted against myocardium at risk (MaR) for the overall
study population (n = 68) at (A) three and (B) 12 months in
patients belonging to the control and postconditioning (PostC)
groups. Significant differences between the slopes of the regression
lines of the two groups are indicated.
Figure 5 Left ventricular ejection fraction (LVEF) plotted
against myocardium at risk (MaR) for the overall study
population (n = 68) at (A) three and (B) 12 months in patients
belonging to the control and postconditioning (PostC) groups.
P-values between the slopes of the regression lines of the two
groups are indicated.
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in patients within the upper quartile of MaR, reflecting
large threatening infarcts. Infarct size was still signifi-
cantly smaller in the PostC group within this quartile.
This could be expected taking previously reported data
on infarction absorption and acute modulation of the re-
perfusion injury into account [12,24,25]. More interest-
ingly, LVEF was higher after 12 months among patients
in the PostC than in the control group. Our data sup-
port and extend the previous long-term observation by
Thibault et al. [14] using echocardiography that LVEF
was higher in the PostC group after one year. OurFigure 4 Box-plot of infarct size in patients within the upper quartile
in the control group and the postconditioning (PostC) group.study is the first to demonstrate both LVEF and infarct
size determined with CMR one year after the initial
event.
The finding that the beneficial effect is found among
patients with large MaR is in accordance with previous
observations. The present study had a comparably small
proportion of LAD infarctions and consequently a mean
MaR of 27% in comparison with a mean MaR in the
magnitude of 35-40% in previous reports demonstrating
a beneficial effect of PostC [7,9,11,14]. Taken together,
available data might indicate that PostC is effective in
patients with large areas of ischemic myocardium and(n = 17) of myocardium at risk (MaR) at (A) 3 and (B) 12 months
Table 3 CMR characteristics for Control and PostC, long-term follow-up
Control, n=35 PostC, n=33
1 week 3 months 12 months 1 week 3 months 12 months
LV end-diastolic volume index, ml/m2 89 (80, 99) 88 (77,103) 86 (70, 104) 79 (73, 84) 85 (77, 99) 79 (73, 91)
LV end-systolic volume index, ml/m2 49 (37, 56) 44 (35, 58) 39 (33, 57) 43 (36, 55) 43 (37, 55) 40 (32, 48)
Sphericity index, end-diastole 0.39 (0.35, 0.42) 0.39 (0.32, 0.47) 0.38 (0.33, 0.44) 0.38 (0.34, 0.45) 0.40 (0.35, 0.44) 0.37 (0.33, 0.44)
LV-mass index, g/m2 68 (60, 75) 61 (55, 69)** 60 (55, 67)***, # 65 (59, 75) 59 (56, 70)*** 57 (54, 68)***
Infarct size, % of LV mass 8.0 (5.5, 14.1) 6.6 (4.3, 13.6)*** 6.0 (4.3, 13.1)*** 9.9 (5.5, 14.9) 8.8 (5.0, 11.5)*** 7.6 (4.9, 12.2)***
Infarct size, g 12.3 (7.5, 23.8) 9.1 (5.4, 21.1)*** 7.8 (4.9, 19.8)***, ## 11.2 (7.7, 25.5) 10.1 (6.2, 18.8)*** 10.6 (5.4, 16.9)***
Infarct size, % of ACS 39 (27, 54) 33 (21, 44)*** 31 (23, 41)*** 41 (26, 54) 31 (22, 45)*** 31 (23, 43)***
Microvascular obstruction (LGE),
% of LV mass
2.0 (1.4, 2.8) - - 1.8 (1.1, 2.8) - -
Median and inter quartile range. ACS Abnormally contracting segments; LGE Late gadolinium enhancement, LV Left ventricle. * p < 0.05; ** p < 0.01; *** p < 0.001
vs. 1 week; # p < 0.05, ## p < 0.01 vs. 3 months. Wilcoxon sign rank test with Bonferroni correction.
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lowing the acute event.
CMR is considered as the reference method for the de-
termination of cardiac volumes and final infarct size due
to its accuracy, reproducibility and ability to detect small
morphological and functional changes [26,27]. LV re-
modeling after myocardial infarction is an important
prognostic factor for progression to heart failure and
subsequent mortality [28]. Multiple factors contribute to
the remodeling process including infarct size, micro-
vascular obstruction, patency of the infarct related artery
and baseline LVEF [29,30]. Recent studies have used
CMR as a tool for identifying predictors of remodeling
in reperfused STEMI populations. Lund et al. [31] dem-
onstrated that an infarct size ≥24% of the LV mass pre-
dicted remodeling with high sensitivity and specificity.
Masci et al. concluded that infarct size rather than loca-
tion and salvage index predicted LV remodeling in
STEMI patients [32,33]. Only nine of the patients in the
present study met the remodeling criteria (a consistent
increase in ESV >15%) and small infarct sizes is the most
reasonable explanation [24,31,32]. In addition the vast
majority of the present patients were treated with beta-
blockers and angiotensin converting enzyme inhibitors,
pharmacological agents known to counteract remodel-
ing. This made the group of patients with adverse re-
modeling too small for accurate analysis of possible
predictors for that process. The end-diastolic sphericity
index, which indicates LV cavity remodeling, did not
change over time within groups indicating that there
was no overall adverse long-term remodeling. The sig-
nificant decrease in LV mass between the first and sec-
ond CMR examination can be explained by resorption of
edema in the infarct territory and replacement with fi-
brosis. The observation that absolute infarct size de-
creased in only the control group between three and
12 months is surprising considering existing data[24,25]. The difference was only 1.3 grams in median
but there is no obvious pathological or physiological
data supporting the notion that a necrotic mass may de-
crease after one year.Limitations
An important limitation of the present study is the small
study population which may result in a type II statistical
error regarding the detection of minor benefits of PostC.
Although, the method of relating infarct size to MaR
and the strong reproducibility of CMR reduces the num-
ber of patients needed to detect differences between
groups. The number of patients was based on a power
calculation assuming a 20% relative reduction of infarct
size by PostC [8]. There was a 24% loss to follow up,
which might induce the risk of selection bias. However,
this risk is minimized due to the fact that the loss was
evenly distributed with 11 patients in the PostC and 10
patients in the control group.
The lack of using direct stenting and presence of col-
laterals could potentially affect infarct size and thereby
the result of the study. Importantly however, these pa-
rameters were equally distributed between the groups.
Still the findings of persistent infarct size reduction and
improved LVEF among patients within the upper quar-
tile of MaR in the PostC group is of considerable and
confirmatory interest. These findings should be consid-
ered when planning future studies.Conclusions
In this long-term follow-up study PostC did not reduce
infarct size in relation to MaR or improved LVEF in the
overall study population. However, the present data sug-
gest that PostC exerts long-term beneficial effects in pa-
tients with large MaR thereby extending previously
published short-term observations.
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